• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy

by July 18, 2024
written by July 18, 2024

Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cancer combination therapy.

Despite the setback, the company remains committed to exploring alternative pathways to bring this promising treatment to market.

The FDA’s recommendation came after Agenus presented results from its Phase 2 study, revealing a 19.4% overall response rate (ORR) and a 90% 6-month survival rate for the 75mg dosage of BOT/BAL.

However, concerns about the therapy’s survival benefits led to a sharp sell-off of Agenus stock, which had seen significant gains earlier in the year.

Dr. Steven O’Day, Agenus’ chief medical officer, emphasized the company’s determination to advance BOT/BAL, including plans to incorporate a BOT monotherapy arm in its upcoming Phase 3 trial.

This strategic move aims to address FDA concerns and pave the way for future regulatory approval.

Financial and analyst insights

Despite the stock’s recent downturn, analysts previously projected a bullish outlook for Agenus, with a consensus “buy” rating and an average price target of $39 per share.

The company’s financial resilience, including ending the first quarter with $52.9 million in cash, underscores its ability to navigate regulatory challenges while advancing its clinical pipeline.

Agenus to meet with European regulators

Looking ahead, Agenus plans strategic engagements with European regulators in the third quarter of 2024 to discuss regulatory pathways for BOT/BAL.

Additionally, the company will present compelling data on the therapy’s efficacy in treating Sarcoma at a prestigious European medical oncology event in September, highlighting its commitment to addressing unmet medical needs.

The FDA’s decision represents a critical juncture for Agenus as it strives to balance scientific innovation with regulatory scrutiny.

While the setback underscores the challenges inherent in drug development, Agenus remains steadfast in its mission to deliver innovative treatments that can potentially transform patient outcomes in oncology.

The post Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Netflix Q2 earnings preview: Wall Street awaits updates on ad-supported model
next post
Domino’s Pizza stock crashes as American consumer struggles with rising food prices

related articles

Asian markets open: Nikkei, Hang Seng fall on...

June 12, 2025

Aluminum and steel tariffs spark rise in secondary...

June 12, 2025

Airbus sees aviation boom ahead, global fleet to...

June 12, 2025

US-China trade talks and Washington’s decade-long effort to...

June 12, 2025

Europe markets open: Stoxx 600 dips as UK...

June 12, 2025

UK GDP falls by 0.3% in April as...

June 12, 2025

Gordon Brothers buys Poundland; pledges £80 mn for...

June 12, 2025

Air India plane crash: London-bound flight with 242...

June 12, 2025

Air India plane crash live update: Indian President...

June 12, 2025

Copper remains supported for now even as China...

June 12, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Speaker Johnson slams Dem Rep. Green’s ‘egregious behavior’ during Trump’s address

    March 6, 2025
  • EXCLUSIVE: GOP moves to defund ‘chronically biased’ NPR, PBS after disastrous hearing

    March 27, 2025
  • The dollar index has a new opportunity to start a recovery

    August 26, 2024
  • Pakistan says it has struck military targets inside India in series of new attacks

    May 10, 2025
  • Fact check: No, Biden has never been a good, honest, or decent man

    July 14, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (5,960)
  • Investing (634)
  • Stock (923)

Latest Posts

  • Who is the conservative ‘superstar’ lawyer and potential SCOTUS pick that will help in Eric Adams case?

    February 26, 2025
  • Truth Social app on the Nasdaq as DJT, closed 16% higher

    November 19, 2024
  • Iran is ‘increasingly aggressive’ in its operations to target US presidential campaigns: Intel community

    August 20, 2024

Recent Posts

  • GOP duo unveils plan to force Congress to ‘face consequences’ as shutdown looms

    September 4, 2025
  • Putin assisting Maduro regime amid ongoing protests over rigged election result

    August 29, 2024
  • India’s 2nd-wealthiest person charged by U.S. in $250 million bribery scheme

    November 21, 2024

Editor’s Pick

  • Gold and Silver: Gold in a new rush to last week’s high

    August 26, 2024
  • Dogecoin and Shiba Inu: Daily Targets and Prices

    September 26, 2024
  • DNC committee moving forward with plans for virtual roll call vote in early August

    July 20, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock